Compound half-life reference

Study endpoint used in an estimated curve. Highly purified urinary hCG, Choriomon, subcutaneous injection; 24 healthy women aged 20–45 in a crossover pharmacokinetic analysis, with oral-contraceptive pituitary downregulation.

Omnitrope solution single-dose study EP2K-00-PhIAQ, N=24; apparent SC tail, not intrinsic IV elimination.

Derived from the published model rates. Subcutaneous semaglutide solution in the SUSTAIN phase III program; Subcutaneous. Published reference: 85 kg white, non-Hispanic female under 65 with type 2 diabetes and normal renal function.

Derived from the published model rates. Original oral semaglutide/SNAC formulation studied with 300 mg SNAC; first-generation Rybelsus context, not newer oral formulations; Oral tablet. Healthy 85 kg adult without type 2 diabetes; fixed published reference parameters, not an average patient.

Derived from the published model rates. Subcutaneous tirzepatide in the published pooled-study model, using its estimated relative-bioavailability scenario; Subcutaneous. Constructed adult female reference with type 2 diabetes: 90 kg and BMI 32.5 kg/m²; not a published average participant.

Coskun 2022 Table 1, 1 mg cohort: geometric mean terminal half-life134h; median Tmax48h.

Innovent Chinese label: Tmax7–28h, rounded mean terminal half-life about10days. Label apparent clearance .0368L/h and volume11.2L.

Nielsen2026 Table5 normal hepatic function: half-life174h and Tmax45h.

NCT01667900, Part A Day1,1.5mg group: median Tmax48h; geometric mean half-life82.9h.

Symlin label Table5: Tmax21minutes=.35h; half-life48minutes=.8h.

Table4 first0.6mg dose Tmax23.7h; Results3.3 reports DG2 terminal half-life114h after repeated/escalated dosing.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Human route/formulation, systemic exposure, absorption and terminal kinetics were not established by the reviewed source. Cell permeability cannot supply oral bioavailability.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• No matched human concentration/time endpoint was verified. Do not translate the primate experimental regimen into human calibration.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Product identity, free-base/salt basis and route must be specified before absolute calibration. The stored 12-hour timing is unsupported, not a source-backed elimination half-life.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not substitute IGF-1, intact IGF1Ec or tissue-expression time courses for isolated MGF blood kinetics.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (4.8 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• PEG size, conjugation and product identity are not specified. A PEG-containing delivery scaffold does not establish the circulation kinetics of a PEG-MGF conjugate.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Tracer radioactivity, parent analyte and human administered-product exposure are not interchangeable. Retained timing is an assumption.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Potency or duration of biological response is not an elimination half-life. No human product/route Cmax was verified.

30µg/kg cohort half-life5.8d from Teichman figure2;1.25h is midpoint assumption within reported1–1.5h peak window, not measured cohort mean.

• The faster rate is inferred to match the 1.25 h source-scoped peak time; absorption half-life 0.12313185117369821 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• No study cohort mean weight recovered, so30µg/kg cannot become2mg or2.1mg without an explicit assumed reference weight.
• AUCt is to last sampling, not infinite; exact last measurable time differs by subject. Do not compare it as if AUCinf.
• DAC albumin-bound analyte assay and formulation are not interchangeable with free no-DAC GRF.
• With139.2h tail and1.25h assumed Tmax, a simple peak-normalized Bateman is unsuitable for reproducing the observed early/late profile.

Retained historical illustrative timing assumption only; no validated human SC half-life recovered for this specific form.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Identity/salt ambiguity persists; no-DAC is not the DAC molecule with a different schedule.
• No measured SC F,Tmax or concentration amplitude supports the current curve.
• Relative output must explicitly identify timing assumption.

Terminal half-life after15min IV infusion in healthy men; extrapolated to SC shape only. SC absorption remains assumed.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.5 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Vss is not automatically central volume in a two-compartment model.
• Do not use GH Cmax, EC50 or production rate as ipamorelin concentration.
• No substantiated human SC F or matched Cmax/ref-dose/Tmax recovered.

Soule1994 human IV disappearance half-time4.3±1.4min; using it for SC is a route extrapolation, not a measured SC terminal value.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.017916666666666668 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Historical Geref11–12min and6%SC figures were located only via secondary mirrors, not a primary label; not silently adopted.
• No matched SC concentration endpoint set recovered; do not borrow GH peaks.

Single EGRIFTA WR1.28mg SC dose in healthy subjects, same label study. Original2mg Egrifta26/38min values came after14days, not this single-dose WR formulation.

• The faster rate is inferred to match the 0.15 h source-scoped peak time; absorption half-life 0.06452204183467626 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Peak/Tmax/tail reconstruction gives AUC1.7866ng·h/mL versus1.172reported (+52.4%); do not call all endpoints reproduced.
• Either explicitly identify WR in model scope or keep generic formulation relative; never relabel saved2mg inputs as1.28mg.
• No additional F multiplier because peak includes availability.
• Source variability is large; means of endpoints need not define one typical individual curve.

Pihoker 1998: terminal beta half-life in prepubertal children with short stature after 1 µg/kg IV over 1 min. Applying this to catalog SC scenarios extrapolates route and population.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.1375 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• No matched adult SC availability, Tmax or dose-calibrated peak recovered.
• The pediatric IV 7.4 ng/mL peak must not be attached to a generic 0.1 mg SC dose.
• A single compartment does not reproduce the source biexponential disposition.

Cabrales 2013: IV terminal half-life 2.5 ± 1.1 h; distribution half-life 7.6 ± 1.9 min. SC absorption was not measured.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.625 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• The study used larger weight-based IV exposures than typical catalog SC scenarios.
• No SC availability, Cmax or Tmax was established.
• This does not model GH concentration.

Historical illustrative assumption. The regulator review found no detailed clinical PK supporting a human plasma half-life. A 24 h GH/IGF effect duration is not a plasma half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.25 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not turn dog bioavailability into human availability.
• No retrieved human paired parent-drug dose, Cmax and Tmax support an absolute scale.
• Future product-specific LUM-201 work may provide calibration; no complete verified candidate was recovered here.

Illustrative midpoint of 12.5 days within the reported human 10–15 day range; not a published cohort mean.

• Absorption half-life is assumed to be one quarter of the slower timescale (75 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not infer a fixed absolute dose from mg/kg without an explicit reference weight.
• Native ActRIIB and the Fc fusion are different molecules.
• The proposed 300 h relative curve uses a range midpoint assumption; it predicts neither blood concentration nor muscle growth.

Dixon 1991: harmonic mean terminal phase of 1.4 h after IV infusion. SC absorption remains unknown.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.35 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• No matched human SC calibration was recovered.
• The week-long radioactivity tail is not parent-acadesine elimination.
• Vss is not central volume; a monoexponential absolute model cannot be inferred from it.

The historical 9.6 h value falls inside the 4–13 h IV CKD label range, but is not a verified SC estimate. SC timing varies with dose and population; label Tmax is 5–24 h.

• Saved numerical amounts retain their original values. No conversion to milligrams or IU is established.
• Absorption half-life is assumed to be one quarter of the slower timescale (2.4 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not reinterpret legacy stored amounts as mass or IU.
• An IU conversion requires a separately verified serialization and migration contract.
• One SC curve cannot represent all CKD, cancer, dialysis and healthy populations.

Proposed 12 h is the midpoint of the Menopur 11–13 h FSH half-life range during multiple dosing. Single-dose Tmax 17.9 h belongs to a different phase and must not be combined blindly.

• Saved numerical amounts retain their original values. No conversion to milligrams or IU is established.
• Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• FSH is not total menotropin, LH or hCG.
• No IU-to-mass conversion is adopted; saved amounts must not be reinterpreted.
• The proposed timing concerns the FSH component and multiple-dose study, not universal menotropin kinetics.
• A future FSH model is feasible after dose-unit mapping, baseline handling and matched model-shape verification.

Human gonadorelin hydrochloride SmPC: rapid plasma hydrolysis with about 4 min half-life; SC/IV diagnostic formulation.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.016666666666666666 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Acetate preparations are not demonstrated bioequivalent.
• The LH diagnostic response is not gonadorelin concentration.
• SC peak and availability remain uncalibrated.

KP54 IV half-life is about 27.6 min; KP10 is about 3.8–4.1 min. Neither establishes SC absorption for the generic product.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.115 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Clarify peptide identity beside the curve; do not silently treat all kisspeptin as KP54.
• Absolute calibration requires a known peptide length, analyte, route, assay and reference dose.
• This curve does not include endogenous peptide or predict gonadotropin responses.

Rat IM 100 microgram/kg saline BPC157: half-life 17.1 min, Tmax 3 min. The 2-person human IV pilot reports safety biomarkers, not peptide concentration calibration.

• The faster rate is inferred to match the 0.05 h source-scoped peak time; absorption half-life 0.009976653025332967 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Animal IM timing does not establish human SC absorption or elimination.
• Do not use total radiolabel half-life: the radiolabel includes metabolites and recycled amino acids.
• Rat/dog Cmax must not be scaled into a human blood estimate.

Ruff 2010:40 healthy volunteers, single 42–1260 mg IV then daily 14 days; dose-dependent half-life. The legacy 1.92 h is not a verified SC half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.48 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Product sequence and route are unresolved for a generic TB-500 entry.
• Do not transplant the full-length IV peak or half-life to the 7-residue fragment.

The 2024 study examines human-serum/enzyme incubations and rat urine. Metabolite detection to 72 h is not the parent plasma half-life; legacy 0.96 h remains an assumption.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• No human parent-peptide systemic calibration established in reviewed sources.
• Ac-LKKTE wound-assay activity is a metabolite effect, not a blood exposure endpoint.

Rost 1999: nine Caucasian volunteers,900 microgram/m² SC, three-way formulation crossover, single and 5 day administration; Tmax 1–2 h, half-life<3 h. Use 2 h/1.5 h as explicitly inferred representative timing, not a reported fitted parameter pair.

• The faster rate is inferred to match the 1.5 h source-scoped peak time; absorption half-life 0.6075545274580504 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Zadaxin/Timosina/Talpha 1-HLR show different exposure.
• The 63 ng/mL at 1.6 mg value is present in a 2024 review but primary product/cohort linkage was not established in this pass.
• Apparent volumes/clearance already include F.

PKARA: healthy male crossover;4 mg SC n 5, Cmax 2.0±0.7 ng/mL, Tmax 6 min, AUC148 ng·min/mL, terminal~20 min. Later clinical paper summarizes~3 ng/mL; do not silently replace the original cohort mean.

• The faster rate is inferred to match the 0.1 h source-scoped peak time; absorption half-life 0.024645183502450502 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Source Cmax 2 ng/mL and AUC148 ng·min/mL imply an AUC/peak ratio 1.233 h; a 20 min/6 min one-compartment curve gives about 71 ng·min/mL, substantially below 148.
• Reported 2/4/6 mg SC peaks 1.6/2.0/7.4 ng/mL are not proportional across all tested amounts.
• Bioavailability and volume must not be invented.

Derived from the published model rates. Elamipretide hydrochloride solution, 40 mg active moiety in 0.5 mL in the source comparator.; Subcutaneous abdomen. Fixed tabulated SPICP-105 parameters from 41 healthy participants; no particular reference age or weight is asserted..

Legacy 12 h has no administered-human timing support in reviewed sources.

• Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not substitute the modified analog CB4211 or engineered R13A-MOTS-c for native MOTS-c.
• Endogenous biomarker concentrations cannot calibrate an entered exogenous dose.

Legacy 0.96 h is a scenario assumption; wound-healing duration and endogenous cathelicidin concentration are not plasma elimination.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Topical/local concentration cannot be scaled to a generic SC blood curve.
• LL-37 analog and carrier/nanoparticle PK does not establish native peptide exposure.

Legacy 0.48 h is not established by the transporter or mouse efficacy study.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Cell-culture nanomolar efficacy and PepT1 uptake kinetics are not plasma concentration-time parameters.
• Oral mouse exposure cannot establish human SC F.

Legacy 0.96 h is an assumed single-timescale approximation, not measured clearance of the extract.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not transfer thymosin alpha 1, thymogen or vilon PK to this mixture.
• Total preparation mass does not identify a circulating peptide analyte.

Domschke 1978: four healthy volunteers,30 min graded IV infusions; approximately 1 min plasma disappearance after stopping infusion. This can inform a fast IV relative scenario, not a validated intranasal profile.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.004166666666666667 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Inhaled, intranasal, intracavernosal and IV aviptadil are not interchangeable.
• A terminal 21 minute phase in other IV studies differs from the initial 1–2 minute disappearance phase.

Replace legacy 0.48 h with the reported horse IM terminal 0.68 h only as an explicitly animal-derived relative scenario. IV distribution 0.09 h and terminal 0.76 h are distinct. Do not apply the horse 47–100%IM bioavailability to people.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.17 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not borrow data for Lys 7-dermorphin fluorescent probes or dermorphin-ranatensin hybrids.
• A human intrathecal dose cannot calibrate a blood curve.

Legacy 0.96 h is a scenario assumption; cell lysis onset and in-vitro exposure duration are not elimination.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Cell-culture concentrations cannot be used as injected blood Cmax.
• Do not substitute PNC-28 or a different delivery conjugate.

Legacy 12 h is not a human measured half-life. D-retro-inverso design or days between mouse doses do not quantify clearance.

• Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Mouse efficacy schedules are not human elimination evidence.
• Different FOXO4 peptide sequences/conjugates cannot share calibration automatically.

Legacy 0.96 h is unverified for administered-human intact GHK-Cu. No quantitative timing is imported from free-GHK degradation.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Free GHK, intact GHK-Cu, total copper and endogenous baseline GHK are different analytes.
• Topical cosmetic concentrations and assay calibration ranges are not plasma Cmax.

Legacy 0.96 h is an assumption; the 10^-12–10^-9M in-vitro range is an experiment concentration, not a PK endpoint.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not borrow GHK-Cu or freeGHK pharmacokinetics.
• No administered-human route-matched absolute calibration established.

Hong 2005: seven fasting male volunteers aged 22–23,50 mg/kg over 10 min IV (meanweight 65.5 kg); rapid parentGSH loss about 10 min. Legacy 0.48 h is not an established generic route half-life. Keep generic relative timing unvalidated until route-specific selection; the 10 min IV measurement is a source observation, not silently adopted for oral orSC dosing.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• ReducedGSH, oxidizedGSSG and totalGSH must be separated.
• The reviewed IV study subtracts baseline for exposure calculations; it cannot be transplanted to oral/IM/SC use.
• A future dedicated IV model needs infusion input and exact analyte-specific table extraction; do not mistake total GSH for the reduced-GSH peak.

Legacy 0.48 h is an assumption, not measured human systemic half-life. Brain residence or 4–8 h effects must not be substituted for blood elimination.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Species/route and parent/metabolite separation remain unresolved for absolute exposure.
• Do not import enkephalin half-life from enzyme-inhibition experiments.

Legacy 0.48 h is unverified; enkephalin half-life is explicitly a different molecule.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not interpret inhibited leu-enkephalin degradation as Selank elimination.
• Intranasal rat brain distribution does not calibrate human SC plasma.

Legacy 0.48 h is not source-backed; evidence reviewed does not establish that acetylation/amidation or another modification confers a numeric extension.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Compound identity can differ among vendor descriptions.
• No compound-specific administered-human calibration established in reviewed records.

Legacy 0.96 h is an assumed display timescale, not measured mixture clearance.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• The 215.2 mg/mL product concentration is preparation mass, not peptide Cmax.
• Do not assign a universal molecular weight to the complex or reinterpret saved milligram amounts as mL.

Legacy 0.96 h is an assumed timescale; cell penetration and neurite changes are not elimination.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Transport-carrier hypotheses do not establish systemic F.
• Fluorescently labeled EDR is not necessarily pharmacokinetically identical to native Pinealon.

Legacy 0.48 h is not measured human elimination. Original paper distinguishes PE22-28 from spadin and modified derivatives.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• IC50 and behavioral effect persistence must not calibrate circulating concentration.
• No human route/dose concentration-time profile established in reviewed sources.

1984 enzyme-immunoassay: four anesthetized dogs,1–2 mg IV; meanhalf-life 4.0±0.7 min; monkey 2.9 min, rats 2.0±0.54 min. A4 min relative timing anchor must be labeled animal IV.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.016666666666666666 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• C-terminal immunoreactivity is less specific than modern intact-peptide LC-MS.
• No human SC absolute calibration established; endogenous protein-bound DSIP-like material is different.

Legacy 0.96 h is a scenario assumption; effects over days and telomere length are not elimination.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Epithalamin extract, parentAEDG and modifiedamidate are distinct preparations.
• No route-matched parent-peptide human concentration calibration established in reviewed sources.

Legacy 1.44 h and a claimed extension over parent 0.96 h are unsupported numerical assumptions.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.36 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• The supplier identity declaration is not a PK study.
• Do not assume a 1.5x half-life multiplier from chemical end-capping.

Legacy 4.08 h is an unverified scenario timescale; no concentration-time sampling in the inspected experiment.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• In-vitro assay concentration is not Cmax.
• Cartilage-patent claims do not establish a clinically measured half-life.

Legacy 4.08 h remains an assumed timescale; inflammatory marker changes do not supply elimination.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Oral capsule directions do not establish peptide bioavailability.
• Do not borrow kinetics from unrelated bronchial peptide mixtures.

Legacy 4.08 h is unverified; five consecutive treatment days do not imply any particular half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Cortagen tetrapeptide is not Cortexin brain extract.
• Clinical-effect assertions in an introduction are not concentration measurements.

Legacy 4.08 h has no measured human timing support in inspected originals.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Tissue specificity in culture cannot provide systemic exposure or F.
• Do not convert a suggested course length into elimination timing.

Legacy 4.08 h remains an assumption; the patent has no verified plasma PK row used here.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Ovagen is also a veterinaryFSH product name; that is not EDL peptide evidence.
• Animal kidney outcomes and small patent-use examples cannot calibrate human blood concentrations.

Legacy 4.08 h is an assumed timescale; the 0.05 ng/mL tissue-culture concentration is not a plasma peak.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not mistake cultured human donor cells for an administered-human study.
• No route-matched human PK established in reviewed sources.

Legacy 4.08 h is unverified; fluorescent-peptide uptake does not establish native peptide elimination.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not equate material-science KEDG adsorption or DNA binding with systemic exposure.
• No human exogenous-peptide calibration established in reviewed sources.

Legacy 4.08 h is an assumption; no timed parent-peptide plasma data in inspected originals.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not substitute activity duration or donor-cell aging endpoints for elimination.
• No route-specific F established.

Legacy 4.08 h is an assumed timescale, not measured elimination.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• VilonKE, ThymogenEW and Thymalincomplex are not interchangeable.
• Culture concentrations and immune-marker changes are not blood exposure.

The illustrative 1.2 h value is inside the human SC solution terminal range of 0.8–1.7 h; reported absorption half-lives were 0.07–0.79 h (Ugwu 1997).

• Absorption half-life is assumed to be one quarter of the slower timescale (0.3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Historical 50% availability contradicts the small human study; it should not be presented as measured.
• No absolute concentration is inferred from a small-sample, weight-normalized clearance range.
• Pigmentation lasting weeks is not the drug plasma half-life.

The historical 2.4 h value remains an illustrative timing assumption, not a confirmed human terminal half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.6 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not borrow bremelanotide parameters simply because the molecules are related.
• Erection duration is a pharmacodynamic outcome, not plasma half-life.
• Failure to recover a human PK dataset is an evidence gap, not proof that no study can exist.

Derived from the published model rates. Vyleesi bremelanotide acetate solution/autoinjector; Subcutaneous abdomen. Fixed 74.5 kg premenopausal woman with HSDD; eGFR 95.22 mL/min/1.73m².

Historical 4.32 min is an illustrative selection inside the label plasma range of 1–6 min; it is not a study mean. Pregnancy and lactation change clearance.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.018 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not infer an IU-to-mass conversion.
• The assumed 10% availability is not a measured product value.
• Intranasal central delivery and peripheral plasma exposure are not interchangeable.

A 1 min relative timing assumption is an upper boundary of the reported rapid IV metabolic half-life, not a measured intracavernosal tissue half-life or erection duration.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.004166666666666667 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Never use endogenous baseline 96 pg/mL as a dose-derived peak.
• A relative systemic timing illustration does not model local tissue exposure or erection duration.
• The route extrapolation must be explicit.

Label apparent terminal half-life of 17.4 h is from uncorrected plasma after 20 mg/kg IV over 3 min; distribution half-life is 0.585 h. Endogenous baseline affects the terminal estimate. This is not a verified IM/SC tail.

• Absorption half-life is assumed to be one quarter of the slower timescale (4.35 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not borrow an oral steady-state peak for injection.
• Label clearance of 4 L/h and terminal 17.4 h include baseline and do not suffice for an exogenous-only model.
• The SC/IM 70% availability assumption is unsupported.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Infusion is not a bolus, oral or SC formulation. Endogenous baseline and rapid uptake/metabolism prevent assigning one observed mixture response as a per-dose Cmax. The 12-hour timing remains illustrative.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.2 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Reviewed evidence does not establish the catalog’s 4.8-hour human half-life or bioavailability. No absolute human Cmax was verified.